Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
donanemab
Biotech
Lilly faces phase 2 failure of tau-targeting med
The confetti is still flying from the approval of donanemab, but Eli Lilly is yet again facing the harsh reality of the Alzheimer's disease.
Annalee Armstrong
,
James Waldron
Aug 8, 2024 10:48am
AbbVie axes Alzheimer's program amid 'evolving landscape'
Jul 25, 2024 10:49am
Lilly's donanemab sails through FDA meeting with 2 yes votes
Jun 10, 2024 5:11pm
FDA lays out donanemab concerns, Lilly vigorously defends safety
Jun 6, 2024 10:55am
Lilly gets a date with FDA to discuss Alzheimer's med donanemab
May 7, 2024 10:20am
Lilly glides out of Leqembi slipstream with FDA meeting request
Apr 17, 2024 5:00am